STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

| | |
|---|---|
| USAN (JK-99) | BERSACAPAVIR |
| PRONUNCIATION | ber” sa kap’ a vir |
| THERAPEUTIC CLAIM | Treatment of hepatitis B virus (HBV) infection |

CHEMICAL NAMES

1 1*H*-Pyrrole-2-carboxamide, *N*-(3-cyano-4-fluorophenyl)-1-methyl-4-[[[(1*S*)-2,2,2-trifluoro-1-methylethyl]amino]sulfonyl]- (CAS Name)

2. *N*-(3-Cyano-4-fluorophenyl)-1-methyl-4-[[[(1*S*)-2,2,2-trifluoro-1-methylethyl]amino]sulfonyl]-1H-pyrrole-2-carboxamide

STRUCTURAL FORMULA




| | |
|---|---|
| MOLECULAR FORMULA | C16 H14 F4 N4 O3 S |
| MOLECULAR WEIGHT | 418.4 Da |
| TRADEMARKS | None as of yet |
| SPONSOR | Janssen |
| CODE DESIGNATIONS | JNJ-56136379; JNJ-6379 |
| CAS REGISTRY NUMBER | 1638266-40-6 |
| UNII | 2456KW2166 |
| WHO NUMBER | 11272 |